Voyager Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview

Voyager Therapeutics

03/05/2024 15:09

* Voyager Therapeutics Inc  VYGR.OQ   VYGR.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * The Lexington Massachusetts-based  company is expected to
report
a 93.7% decrease in revenue to $9.415 million from $150.48
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Voyager Therapeutics Inc
is
for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Voyager
Therapeutics Inc is $18.00​, above​ its last closing price
of $8.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.16       -0.29      1.25      Beat    533.2
 Sep. 30 2023  -0.57       -0.58      -0.59     Missed  -1.5
 Jun. 30 2023  -0.57       -0.57      -0.51     Beat    10.3​
 Jan. 1 0001   1.00        0.77       2.94      Beat    281
 ​​Dec.        -0.54       -0.55      -0.61     Missed  -11.5
 31 2022                                                
 Jan. 1 0001   -0.31       -0.32      0.45      Beat    241.9​
 Jun. 30 2022  -0.48       -0.32      -0.50     Missed  -57.5
 Mar. 31 2022  -0.25       -0.34      -0.56     Missed  -62.7
 This summary was machine generated May 3 at 14:09 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)